Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arata Azuma

Showing results (131-140 of 221) with videos related to

Pageof 23
Sort By:
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|March 20, 2003
[Clinicopathological analysis of patients with idiopathic pulmonary fibrosis which became acutely exacerbated after video-assisted thoracoscopic surgical lung biopsy]Tatsuji Enomoto, Masashi Kawamoto, Shinobu Kunugi, et al.
RMD Open|February 23, 2025
Continued nintedanib in patients with systemic sclerosis-associated interstitial lung disease: 3-year data from SENSCIS-ONYannick Allanore, Madelon C Vonk, Oliver Distler, et al.
Journal of Comparative Effectiveness Research|December 20, 2022
Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
Pulmonary Pharmacology & Therapeutics|January 8, 2013
EM, EM703 inhibit NF-kB activation induced by oxidative stress from diesel exhaust particle in human bronchial epithelial cells: importance in IL-8 transcriptionYing-Ji Li, Takako Shimizu, Yukiyo Hirata, et al.
The New England Journal of Medicine|May 15, 2022
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary FibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
Respiratory Investigation|September 8, 2015
All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosisTakashi Ogura, Arata Azuma, Yoshikazu Inoue, et al.
Respiratory Investigation|December 13, 2024
Direct hemoperfusion with polymyxin B immobilized fiber column (PMX) treatment for acute exacerbation of idiopathic pulmonary fibrosis: A prospective multicenter cohort studyShinji Abe, Arata Azuma, Yoshinobu Saito, et al.
International Cancer Conference Journal|June 1, 2019
Granuloma-forming interstitial pneumonia induced by nivolumab: a possible immune-related adverse event of the lungTakeru Kashiwada, Yoshinobu Saito, Yuji Minegishi, et al.
Antioxidants & Redox Signaling|January 6, 2023
Core Fucosylation Is Required for the Secretion of and the Enzymatic Activity of SOD3 in Nonsmall-Cell Lung Cancer CellsYuki Ohkawa, Masato Kitano, Kento Maeda, et al.
American Journal of Respiratory and Critical Care Medicine|January 25, 2005
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosisArata Azuma, Toshihiro Nukiwa, Eiyasu Tsuboi, et al.
Pageof 23

Showing results (131-140 of 221) with videos related to

Sort By:
Pageof 23
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|March 20, 2003
[Clinicopathological analysis of patients with idiopathic pulmonary fibrosis which became acutely exacerbated after video-assisted thoracoscopic surgical lung biopsy]Tatsuji Enomoto, Masashi Kawamoto, Shinobu Kunugi, et al.
RMD Open|February 23, 2025
Continued nintedanib in patients with systemic sclerosis-associated interstitial lung disease: 3-year data from SENSCIS-ONYannick Allanore, Madelon C Vonk, Oliver Distler, et al.
Journal of Comparative Effectiveness Research|December 20, 2022
Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
Pulmonary Pharmacology & Therapeutics|January 8, 2013
EM, EM703 inhibit NF-kB activation induced by oxidative stress from diesel exhaust particle in human bronchial epithelial cells: importance in IL-8 transcriptionYing-Ji Li, Takako Shimizu, Yukiyo Hirata, et al.
The New England Journal of Medicine|May 15, 2022
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary FibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
Respiratory Investigation|September 8, 2015
All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosisTakashi Ogura, Arata Azuma, Yoshikazu Inoue, et al.
Respiratory Investigation|December 13, 2024
Direct hemoperfusion with polymyxin B immobilized fiber column (PMX) treatment for acute exacerbation of idiopathic pulmonary fibrosis: A prospective multicenter cohort studyShinji Abe, Arata Azuma, Yoshinobu Saito, et al.
International Cancer Conference Journal|June 1, 2019
Granuloma-forming interstitial pneumonia induced by nivolumab: a possible immune-related adverse event of the lungTakeru Kashiwada, Yoshinobu Saito, Yuji Minegishi, et al.
Antioxidants & Redox Signaling|January 6, 2023
Core Fucosylation Is Required for the Secretion of and the Enzymatic Activity of SOD3 in Nonsmall-Cell Lung Cancer CellsYuki Ohkawa, Masato Kitano, Kento Maeda, et al.
American Journal of Respiratory and Critical Care Medicine|January 25, 2005
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosisArata Azuma, Toshihiro Nukiwa, Eiyasu Tsuboi, et al.
Pageof 23